In vivo activity of MiR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Di Martino, Maria Teresa ^a,b   Campani, Virginia ^c   Misso, Gabriella ^d   Gallo Cantafio, Maria Eugenia ^a   Gullà, Annamaria ^a   Foresta, Umberto ^a   Guzzi, Pietro Hiram ^e   Castellano, Maria ^d   Grimaldi, Anna ^d   Gigantino, Vincenzo ^f   Franco, Renato ^f   Lusa, Sara ^c   Cannataro, Mario ^e   Tagliaferri, Pierosandro ^a,b   De Rosa, Giuseppe ^c   Tassone, Pierfrancesco ^a,b,g   Caraglia, Michele ^d,g  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Oncologic Surgery   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e Salvatore Venuta University Campus   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 6; MICRORNA 34A; MITOGEN ACTIVATED PROTEIN KINASE 1; NANOCARRIER; NOTCH1 RECEPTOR; PROTEIN KINASE B; STABLE NUCLEIC ACID LIPID PARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; ENCAPSULATION; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; SCID MOUSE; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TRANSFER TECHNIQUES; HUMANS; MALE; MICE; MICRORNAS; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897872063     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090005     Document Type: Article

References (49)

1. Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D, et al. (2007) miRNAs and their potential for use against cancer and other diseases. Future Oncol 3: 521-537. (Pubitemid 47595862)
2. Trang P, Weidhaas JB, Slack FJ (2008) MicroRNAs as potential cancer therapeutics. Oncogene 27 Suppl 2: S52-57.
3. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, et al. (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773. (Pubitemid 40292988)
4. Bravo V, Rosero S, Ricordi C, Pastori RL (2007) Instability of miRNA and cDNAs derivatives in RNA preparations. Biochem Biophys Res Commun 353: 1052-1055. (Pubitemid 46080404)
5. De Rosa G, De Stefano D, Galeone A (2010) Oligonucleotide delivery in cancer therapy. Expert Opin Drug Deliv 7: 1263-1278.
6. Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, et al. (2001) Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510: 152-166. (Pubitemid 32149893)
7. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, et al. (2006) RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
8. Hermeking H (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17: 193-199.
9. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, et al. (2007) p53- mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17: 1298-1307. (Pubitemid 47176893)
10. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745-752. (Pubitemid 46856245)
11. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134. (Pubitemid 47014436)
12. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, et al. (2007) Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1586-1593. (Pubitemid 47327945)
13. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H (2007) Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 104: 15472-15477. (Pubitemid 47502941)
14. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731-743. (Pubitemid 46856247)
15. Chim CS, Wong KY, Qi Y, Loong F, Lam WL, et al. (2010) Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 31: 745-750.
16. Ji Q, Hao X, Zhang M, Tang W, Yang M, et al. (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4: e6816.
17. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215.
18. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, et al. (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70: 5923-5930.
19. Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, et al. (2012) Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets 12: 757-767.
20. Lionetti M, Agnelli L, Lombardi L, Tassone P, Neri A (2012) MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 12: 823-837.
21. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, et al. (2012) DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 3: 1246-1258.
22. Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, et al. (2012) miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis 3: e436.
23. Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, et al. (2013) Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 19: 2096-2106.
24. Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, et al. (2013) miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol 228: 1506-1515.
25. Di Martino MT, Gulla A, Cantafio ME, Lionetti M, Leone E, et al. (2013) In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 4: 242-255.
26. Amodio N, Bellizzi D, Leotta M, Raimondi L, Biamonte L, et al. (2013) miR- 29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle 12.
27. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, et al. (2012) Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 18: 6260-6270.
28. de Antonellis P, Medaglia C, Cusanelli E, Andolfo I, Liguori L, et al. (2011) MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One 6: e24584.
29. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, et al. (2012) Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 12: 838-846.
30. Stewart JC (1980) Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 104: 10-14.
31. Li C, Wong WH (2001) Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 98: 31-36. (Pubitemid 32095858)
32. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, et al. (2008) In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 143: 520-531.
33. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
34. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 115: 787-798. (Pubitemid 38058492)
35. Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13.
36. Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, et al. (2007) Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res 13: 3771-3775. (Pubitemid 47037580)
37. Tu Y, Gardner A, Lichtenstein A (2000) The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokinedependent survival and proliferative responses. Cancer Res 60: 6763-6770.
38. Tassone P, Neri P, Burger R, Di Martino MT, Leone E, et al. (2012) Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets 12: 814-822.
39. Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, et al. (2011) A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 25: 707-711.
40. Tassone P, Neri P, Kutok JL, Tournilhac O, Santos DD, et al. (2005) A SCID-hu in vivo model of human Waldenstrom macroglobulinemia. Blood 106: 1341-1345. (Pubitemid 41129599)
41. Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, et al. (2005) A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 106: 713-716. (Pubitemid 40981270)
42. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, et al. (2012) Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 9: 135-143.
43. Rossi M, Amodio N, Di Martino MT, Caracciolo D, Tagliaferri P, et al. (2013) From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. Curr Drug Targets 14: 1144-1149.
44. Amodio N, Di Martino MT, Neri A, Tagliaferri P, Tassone P (2013) Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther 13 Suppl 1: S125-137.
45. Lal A, Thomas MP, Altschuler G, Navarro F, O'Day E, et al. (2011) Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet 7: e1002363.
46. MackiewiczM, Huppi K, Pitt JJ, Dorsey TH, Ambs S, et al. (2011) Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 130: 663-679.
47. Maeda H (2012) Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 164: 138-144.
48. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, et al. (2009) Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 119: 661-673.
49. Lee YH, Judge AD, Seo D, Kitade M, Gomez-Quiroz LE, et al. (2011) Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene 30: 4175-4184.